IDDI WEBINAR: Design and Analysis of Phase II Trials in Oncology

(1:7:55)

IDDI WEBINAR: The need for better endpoints: Towards a more efficient drug development in oncology

(53:58)

IDDI WEBINAR: The Future of Cancer Clinical Trials

(1:41)

IDDI WEBINAR: A new method to assess treatment benefit/risk, with examples in oncology

(1:34)

IDDI WEBINAR: Personalized cancer medicine needs randomized trials

(59:12)

IDDI WEBINAR: Biomarker based clinical trial designs

(53:21)

IDDI WEBINAR: Efficient designs for Phase I trials in oncology

(58:43)

IDDI WEBINAR: Incorporating HTA in clinical trials

(59:46)

IDDI WEBINAR: Treatment Allocation in Randomized Trials: Challenges and Best Practices

(1:50)

IDDI WEBINAR: Operational Aspects of Data Monitoring Committees

(1:2:6)

IDDI WEBINAR: FRUITFUL CRO COLLABORATION: HOW TO SUCCEED

(38:51)

IDDI Webinar: Central statistical monitoring of clinical trials

(58:8)

IDDI WEBINAR: Current status of surrogates for survival in cancer trials

(59:23)

IDDI WEBINAR: Data Monitoring Committees for Today and Tomorrow

(1:10:24)

IDDI WEBINAR: Tumor-size based measurements as endpoint in cancer clinical trials

(59:41)

Practice Oriented Pragmatic Trials can Integrate Innovations More Rapidly in Evidence Based Medicine

(1:1:14)

IDDI WEBINAR: Patient-Level Data Sharing

(6:2)

IDDI WEBINAR: From Biomarker to IVD: how to design efficient analytical validation studies

(50:56)

IDDI WEBINAR: Pros and Cons of Adaptive Designs

(1:7:56)